- Home
- LYEL vs RILYP Comparison
LYEL vs RILYP Comparison
Compare LYEL & RILYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$21.21
Company Overview
Basic Information| Metric | LYEL | RILYP |
|---|---|---|
| Founded | 2018 | 1973 |
| Country | United States | United States |
| Employees | N/A | 2056 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | N/A |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYEL | RILYP |
|---|---|---|
| Price | $21.21 | $11.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.25 | N/A |
| AVG Volume (30 Days) | ★ 82.2K | 22.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.03% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $36,000.00 | ★ $854,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,438.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $1.75 |
| 52 Week High | $45.00 | $14.50 |
Technical Indicators
Market Signals| Indicator | LYEL | RILYP |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 62.10 |
| Support Level | $16.20 | $8.56 |
| Resistance Level | $27.30 | $11.47 |
| Average True Range (ATR) | 1.83 | 0.87 |
| MACD | 0.13 | 0.11 |
| Stochastic Oscillator | 73.02 | 64.17 |
Price Performance
Historical Comparison LYEL
RILYP
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.